{"id":"lansoprazole-prevacid","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Headache"},{"rate":"8-10%","effect":"Diarrhea"},{"rate":"5-8%","effect":"Abdominal pain"},{"rate":"4-6%","effect":"Nausea"},{"rate":"3-5%","effect":"Constipation"},{"rate":null,"effect":"Vitamin B12 deficiency (long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing both basal and stimulated acid secretion. The effect is dose-dependent and provides sustained acid suppression, allowing healing of acid-damaged tissues.","oneSentence":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:39.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Erosive esophagitis"},{"name":"Pathological hypersecretory conditions"}]},"trialDetails":[{"nctId":"NCT02615184","phase":"PHASE2","title":"A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-05-23","conditions":"Erosive Esophagitis","enrollment":76},{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT07479056","phase":"NA","title":"Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention","status":"RECRUITING","sponsor":"SUK MIN SEO","startDate":"2024-10-24","conditions":"Diseases of the Circulatory System, Angina Pectoris, Unspecified","enrollment":400},{"nctId":"NCT05761015","phase":"PHASE4","title":"Helping Osteoarthritis Patients to Walk With NSAID","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2023-12-14","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip, Chronic Pain","enrollment":55},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT05899842","phase":"NA","title":"Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-06-01","conditions":"Esophageal Achalasia","enrollment":132},{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT02616302","phase":"PHASE2","title":"A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-02-20","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":70},{"nctId":"NCT05946135","phase":"PHASE4","title":"Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2023-11-07","conditions":"Patients on Treatment With Systemic Steroids","enrollment":42},{"nctId":"NCT07337655","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-10-01","conditions":"Pre-term Birth","enrollment":670},{"nctId":"NCT07313774","phase":"PHASE3","title":"A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)","status":"NOT_YET_RECRUITING","sponsor":"Cinclus Pharma Holding AB","startDate":"2026-03","conditions":"GERD (Gastroesophageal Reflux Disease)","enrollment":1050},{"nctId":"NCT04965298","phase":"PHASE3","title":"Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole","status":"RECRUITING","sponsor":"Norfolk and Norwich University Hospitals NHS Foundation Trust","startDate":"2021-06-16","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":298},{"nctId":"NCT05926804","phase":"NA","title":"A \"Screen and Treat\" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile","status":"RECRUITING","sponsor":"Miguel O'Ryan Gallardo","startDate":"2022-08-02","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT04188119","phase":"PHASE2","title":"A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","status":"WITHDRAWN","sponsor":"The Christie NHS Foundation Trust","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT06945237","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2025-04-24","conditions":"Gastroesophageal Reflux Disease","enrollment":164},{"nctId":"NCT07037875","phase":"PHASE3","title":"A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)","status":"NOT_YET_RECRUITING","sponsor":"Cinclus Pharma Holding AB","startDate":"2025-09","conditions":"GERD (Gastroesophageal Reflux Disease)","enrollment":500},{"nctId":"NCT03015610","phase":"PHASE3","title":"Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Jason Lang, M.D., M.P.H.","startDate":"2017-10-31","conditions":"Asthma, Gastroesophageal Reflux","enrollment":41},{"nctId":"NCT07079540","phase":"PHASE3","title":"The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2021-06-24","conditions":"Reflux Esophagitis","enrollment":380},{"nctId":"NCT07076914","phase":"PHASE2","title":"Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2025-10-02","conditions":"Primary Lung Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT04531475","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2020-01-21","conditions":"Reflux Esophagitis","enrollment":90},{"nctId":"NCT06284876","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-07-23","conditions":"Peptic Ulcer","enrollment":416},{"nctId":"NCT06894992","phase":"NA","title":"Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment","status":"RECRUITING","sponsor":"Mario Steffanus","startDate":"2025-05-01","conditions":"Peptic Ulcer Bleeding","enrollment":162},{"nctId":"NCT06964334","phase":"PHASE3","title":"The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-06-01","conditions":"Helicobacter Pylori Infection","enrollment":70},{"nctId":"NCT03130452","phase":"PHASE4","title":"Helicobacter Pylori Eradication Study","status":"COMPLETED","sponsor":"Inje University","startDate":"2016-12-17","conditions":"Helicobacter Pylori Infection","enrollment":423},{"nctId":"NCT04448028","phase":"PHASE4","title":"Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-04-22","conditions":"Liver Cirrhosis","enrollment":476},{"nctId":"NCT06931223","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-10","conditions":"Functioanl Dyspepsia","enrollment":200},{"nctId":"NCT06778395","phase":"PHASE4","title":"Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Ayman Magd Eldin Mohammad Sadek","startDate":"2024-10-01","conditions":"Vonoprazan, Proton Pump Inhibitor, Gastroesophageal Reflux Disease","enrollment":136},{"nctId":"NCT04453189","phase":"PHASE1","title":"A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-20","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT06778824","phase":"NA","title":"Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","status":"RECRUITING","sponsor":"Hualien Tzu Chi General Hospital","startDate":"2024-04-02","conditions":"Gut-Brain Disorders, GERD Without Erosive Esophagitis","enrollment":610},{"nctId":"NCT02112214","phase":"PHASE3","title":"Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2014-06","conditions":"Gastric Cancer, Helicobacter Pylori Infection","enrollment":5224},{"nctId":"NCT04423588","phase":"PHASE4","title":"Dexlansoprazole Absorption and Marginal Ulceration After Gastric Bypass","status":"WITHDRAWN","sponsor":"Spital Limmattal Schlieren","startDate":"2022-01-01","conditions":"Bariatric Surgery","enrollment":""},{"nctId":"NCT04834752","phase":"","title":"Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2021-05-01","conditions":"COVID-19","enrollment":400000},{"nctId":"NCT02387203","phase":"PHASE2","title":"Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mercy Medical Center","startDate":"2015-01","conditions":"Pseudomyxoma Peritonei, Appendiceal Neoplasms","enrollment":80},{"nctId":"NCT06348420","phase":"NA","title":"Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-09-10","conditions":"Gastroesophageal Reflux Disease","enrollment":74},{"nctId":"NCT05448001","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer","status":"COMPLETED","sponsor":"Onconic Therapeutics Inc.","startDate":"2022-09-19","conditions":"Gastric Ulcer","enrollment":329},{"nctId":"NCT06025773","phase":"PHASE1","title":"A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2023-09-15","conditions":"Gastro Esophageal Reflux","enrollment":24},{"nctId":"NCT04784910","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-05-21","conditions":"Peptic Ulcer","enrollment":423},{"nctId":"NCT01216293","phase":"PHASE1","title":"Effect of Dexlansoprazole on Bone Homeostasis","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-11-01","conditions":"Homeostasis, Bone and Bones","enrollment":115},{"nctId":"NCT06268834","phase":"NA","title":"Is Long-Term Proton Pump Inhibitor Use a Cause of Leaky Gut Syndrome","status":"COMPLETED","sponsor":"Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital","startDate":"2023-10-04","conditions":"Proton Pump Inhibitor Adverse Reaction","enrollment":75},{"nctId":"NCT03675672","phase":"PHASE4","title":"Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2018-06-21","conditions":"Active Peptic Ulcer Disease/GI Bleeding","enrollment":154},{"nctId":"NCT05050188","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008","status":"COMPLETED","sponsor":"Jiangsu Carephar Pharmaceutical Co., Ltd.","startDate":"2021-06-24","conditions":"Erosive Esophagitis","enrollment":24},{"nctId":"NCT02679508","phase":"PHASE4","title":"Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-20","conditions":"Erosive Esophagitis","enrollment":208},{"nctId":"NCT04877834","phase":"PHASE1","title":"Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects.","status":"COMPLETED","sponsor":"University of Karachi","startDate":"2021-09-18","conditions":"Healthy, Bioequivalence Study","enrollment":60},{"nctId":"NCT01678027","phase":"PHASE3","title":"Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2004-11","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Family Members","enrollment":1838},{"nctId":"NCT05055128","phase":"PHASE2","title":"A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole","status":"COMPLETED","sponsor":"Cinclus Pharma AG","startDate":"2021-08-11","conditions":"Erosive Esophagitis","enrollment":248},{"nctId":"NCT05624229","phase":"PHASE4","title":"Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-10-01","conditions":"Upper Gastrointestinal Hemorrhage","enrollment":672},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT04840550","phase":"PHASE3","title":"Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2021-05-07","conditions":"Preventive Peptic Ulcer","enrollment":390},{"nctId":"NCT05933031","phase":"PHASE2","title":"Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-27","conditions":"Helicobacter Pylori Infection","enrollment":381},{"nctId":"NCT05861687","phase":"PHASE2, PHASE3","title":"Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children","status":"COMPLETED","sponsor":"Finni Kollins","startDate":"2021-08-01","conditions":"Helicobacter Pylori Infection","enrollment":51},{"nctId":"NCT05010954","phase":"PHASE3","title":"Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2021-10-18","conditions":"Duodenal Ulcer","enrollment":400},{"nctId":"NCT05820048","phase":"PHASE4","title":"The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)","status":"UNKNOWN","sponsor":"Daejeon St. Mary's hospital","startDate":"2023-05-01","conditions":"Coronary Artery Disease","enrollment":300},{"nctId":"NCT05813561","phase":"PHASE3","title":"The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-12-30","conditions":"Reflux Esophagitis","enrollment":332},{"nctId":"NCT04729101","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2021-01-28","conditions":"Healthy Participants","enrollment":44},{"nctId":"NCT04713670","phase":"PHASE4","title":"Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-03-10","conditions":"H. Pylori Infection","enrollment":1200},{"nctId":"NCT05711810","phase":"PHASE4","title":"Medicine-induced Cardiac Hemodialysis on COVID-19","status":"COMPLETED","sponsor":"Yang I. Pachankis","startDate":"2023-01-02","conditions":"Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines","enrollment":1},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT04022096","phase":"PHASE3","title":"Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-06-18","conditions":"Healed Erosive Esophagitis","enrollment":351},{"nctId":"NCT03202537","phase":"EARLY_PHASE1","title":"Effectiveness of Physiologic Testing in PPI Non-Responders","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-07-01","conditions":"Gastro Esophageal Reflux","enrollment":240},{"nctId":"NCT05674864","phase":"NA","title":"Effect of Probiotics on Eradication of Persistent H.Pylori Infection","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-01-01","conditions":"Persistent Helicobacter Pylori Infection","enrollment":92},{"nctId":"NCT03355170","phase":"PHASE4","title":"Cardiac Safety of Lansoprazole and Domperidon Combination","status":"WITHDRAWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-01","conditions":"GERD, Cardiac Event, Safety Issues","enrollment":""},{"nctId":"NCT00825630","phase":"PHASE4","title":"13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":123},{"nctId":"NCT04874935","phase":"PHASE3","title":"The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-06-10","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT02022280","phase":"PHASE1","title":"Effect of Proton Pump Inhibitors on Endothelial Function","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-03","conditions":"Endothelial Dysfunction","enrollment":21},{"nctId":"NCT04124926","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-10-28","conditions":"Erosive Esophagitis","enrollment":1027},{"nctId":"NCT05267743","phase":"PHASE4","title":"Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2021-02-16","conditions":"Erosive Reflux Disease","enrollment":218},{"nctId":"NCT05417997","phase":"PHASE3","title":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","status":"COMPLETED","sponsor":"RAAS Nutritionals, LLC","startDate":"2021-05-29","conditions":"COVID-19 Respiratory Infection, FLU, Cold; Influenza","enrollment":71},{"nctId":"NCT01506986","phase":"PHASE4","title":"Helicobacter Eradication Aspirin Trial","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2012-03","conditions":"Gastrointestinal Ulcer Haemorrhage, Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":30024},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":"Helicobacter Pylori Infection","enrollment":1046},{"nctId":"NCT03094416","phase":"PHASE4","title":"Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2018-07-30","conditions":"Hypothyroidism;Postablative","enrollment":66},{"nctId":"NCT05301725","phase":"","title":"Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy Against Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori; Eradication Rate","enrollment":670},{"nctId":"NCT05259007","phase":"PHASE4","title":"Effect of Propolis on Patients Infected With H. Pylori","status":"UNKNOWN","sponsor":"Fatma Zehra Arvas","startDate":"2022-02-22","conditions":"Helicobacter Pylori Infection","enrollment":96},{"nctId":"NCT04674774","phase":"NA","title":"Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Incheon St.Mary's Hospital","startDate":"2021-03-04","conditions":"Helicobacter Pylori Infection","enrollment":217},{"nctId":"NCT02788591","phase":"NA","title":"Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection","status":"TERMINATED","sponsor":"LCMC Health","startDate":"2015-08","conditions":"Non-erosive Reflux Disease, Gastroesophageal Reflux","enrollment":5},{"nctId":"NCT04814316","phase":"","title":"Effects of Lansoprazole on Bone Turnover Markers","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2019-12-02","conditions":"Bone Turnover Rate Disorder, Calcium Metabolism Disorders","enrollment":60},{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT00472186","phase":"PHASE4","title":"The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2008-06","conditions":"Post-tonsillectomy Pain, Post-tonsillectomy Activity, Post-tonsillectomy Hydration","enrollment":2},{"nctId":"NCT04122287","phase":"PHASE4","title":"Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-11-01","conditions":"Helicobacter Pylori Infection","enrollment":250},{"nctId":"NCT03317223","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2017-10-17","conditions":"Helicobacter Pylori Infection","enrollment":350},{"nctId":"NCT03192059","phase":"PHASE2","title":"Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-07-01","conditions":"Cervical Cancer, Endometrial Cancer, Uterine Cancer","enrollment":43},{"nctId":"NCT03050307","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-17","conditions":"Gastric Ulcer","enrollment":234},{"nctId":"NCT04325633","phase":"PHASE3","title":"Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-24","conditions":"COVID-19","enrollment":30},{"nctId":"NCT00978016","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-09","conditions":"Gastroesophageal Reflux Disease","enrollment":460},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT04660461","phase":"PHASE4","title":"Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2020-02-04","conditions":"Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)","enrollment":20},{"nctId":"NCT02646332","phase":"NA","title":"Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2015-12","conditions":"Helicobacter Pylori Infection","enrollment":248},{"nctId":"NCT04341428","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-07-02","conditions":"Healed Erosive Esophagitis","enrollment":406},{"nctId":"NCT03716622","phase":"PHASE4","title":"A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2018-07-31","conditions":"Helicobacter Pylori","enrollment":350},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533},{"nctId":"NCT04400136","phase":"EARLY_PHASE1","title":"PPI Therapy Impact on GERD After Sleeve Gastrectomy","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2020-07-01","conditions":"Gastro Esophageal Reflux, Barrett Esophagus, Bariatric Surgery Candidate","enrollment":45},{"nctId":"NCT01568944","phase":"NA","title":"Role of Infected Blood Dendritic Cells in Heart Disease Risk","status":"COMPLETED","sponsor":"Augusta University","startDate":"2012-03","conditions":"Chronic Periodontitis","enrollment":18},{"nctId":"NCT03498456","phase":"PHASE3","title":"Triple Therapy With Tegoprazan in H. Pylori Positive Patients","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-06-28","conditions":"Helicobacter Pylori Infection","enrollment":284},{"nctId":"NCT03710434","phase":"PHASE1","title":"AZD4635 Relative Bioavailability Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-11-01","conditions":"Healthy Volunteers","enrollment":21},{"nctId":"NCT02442752","phase":"PHASE1","title":"Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2025-06-15","conditions":"Pediatric Gastroesophageal Reflux Disease","enrollment":""},{"nctId":"NCT04311541","phase":"","title":"A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2020-03-15","conditions":"Gastroesophageal Reflux Disease","enrollment":""},{"nctId":"NCT02557932","phase":"PHASE3","title":"Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-09","conditions":"Helicobacter Pylori Infection, Family History of Stomach Cancer","enrollment":352},{"nctId":"NCT03801148","phase":"PHASE1","title":"A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-01-10","conditions":"Healthy Volunteers","enrollment":122},{"nctId":"NCT02388737","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-04-01","conditions":"Erosive Esophagitis","enrollment":703},{"nctId":"NCT01123031","phase":"PHASE4","title":"Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)","status":"WITHDRAWN","sponsor":"Changhua Christian Hospital","startDate":"2010-04","conditions":"Upper Gastrointestinal Bleeding","enrollment":""},{"nctId":"NCT01681186","phase":"PHASE1","title":"A Study of LY2940680 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-09","conditions":"Healthy Participants","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lansoprazole is marketed as Prevacid."],"phase":"marketed","status":"active","brandName":"Lansoprazole (Prevacid)","genericName":"Lansoprazole (Prevacid)","companyName":"Charles Mel Wilcox, MD","companyId":"charles-mel-wilcox-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}